Skip to main content
. 2022 Feb 13;9(4):ofac078. doi: 10.1093/ofid/ofac078

Table 1.

Demographics, Clinical Characteristics, and Factors Associated With Candidemia Among COVID-19 Patients

Characteristics All Patients
(n = 148)
Candidemia
(n = 28)
No Candidemia
(n = 120)
Univariate Analysis
P Values
Logistic Regression no. 1
P Values
Odds Ratio (95% CI)
Logistic Regression no. 2
P Values
Odds Ratio (95% CI)
Demographics and Underlying Diseases
Age in years, median (IQR) 68 (60–76) 65 (50–73) 70 (60–78) .13
Male sex 65% (96) 75% (21) 62% (75) .77
Cerebrovascular accident 2% (3) 7% (2) 0.8% (1) .09
Cardiovascular disease 19% (28) 18% (5) 19% (23) 1.0
Chronic lung disease 14% (33) 24% (29) 18% (22) .32
Chronic intestinal disease 6% (9) 14% (4) 4% (5) .07
Chronic liver disease 2% (3) 0% 3% (3) 1.0
Chronic kidney disease 19% (28) 14% (4) 20% (24) .60
Solid organ malignancy 13% (19) 21% (6) 11% (13) .20
Hematologic malignancy 3% (5) 7% (2) 3% (3) .24
Immunocompromised status 18% (26) 32% (9) 14% (17) .049 .34 .75
Hypertension 51% (75) 39% (11) 53% (64) .21
Diabetes mellitus 35% (52) 21% (6) 38% (46) .12
No known underlying disease 11% (17) 7% (2) 12% (15) .53
Events Occurred While Inpatient
Receipt of any antimicrobial agent 99% (147) 100% (28) 99% (119) 1.0
Fluoroquinolones 70% (103) 75% (21) 68% (82) .65
Carbapenemsa 68% (100) 86% (24) 63% (76) .025 .008
6.0 (1.61–22.3)
.02
6.2 (1.4–28.1)
Anti-pseudomonal agents (β-lactam, monobactam or carbapenem) 78% (114) 67% (18) 80% (96) .20
β-lactam agents without anti-pseudomonal coverage 12% (17) 4% (1) 13% (16) .31
Glycopeptide/oxazolidinone/cyclic lipopeptide class 49% (72) 54% (14) 48% (58) .67
Polymyxin class 22% (32) 31% (8) 20% (24) .29
Receipt of corticosteroid 84% (125) 71% (20) 88% (105) .045
Presence of central venous catheter.
Duration of central venous catheter, days (median, IQR)
53% (78)
11 days (5–18)
86% (24)
18.5 days (10–25)
45% (54)
8 days (4–15)
<.0001
.0001
.017
4.3 (1.3–14.2)
.11
Requirement for mechanical intubation 84% (125) 89% (25) 83% (100) .57
Shock requiring pressor support 81% (104) 75% (21) 82% (83) .422
Bacteremia
Preceding bacteremiab 26% (39) 71% (20) 16% (19) <.0001 .001
6.6 (2.1–20.1)
Preceding bacteremia due to coagulase-negative Staphylococcus 15% (24) 50% (14) 9% (11) 0.0001 <.0001
13.5 (3.3–55.3)
Preceding bacteremia due to Acinetobacter baumannii complex 9% (13) 39% (11) 2% (2) <.0001 <.0001
48.1 (5.9–391.0)

Abbreviations: CI, confidence interval; IQR, interquartile range.

Among patients receiving carbapenem, all received meropenem; 2 patients received both meropenem and ertapenem but at different times.

Please refer to Supplemental Figure 2 for enumeration of specific bacteria responsible for bloodstream infections among patients with and without bacteremia.